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ABSTRACT
ObjeCtive
To assess the risks of amputation, blindness, severe 
kidney failure, hyperglycaemia, and hypoglycaemia in 
patients with type 2 diabetes associated with 
prescribed diabetes drugs, particularly newer agents 
including gliptins or glitazones (thiazolidinediones).
Design
Open cohort study in primary care.
setting
1243 practices contributing data to the QResearch 
database in England.
PartiCiPants
469 688 patients with type 2 diabetes aged 25-84 
years between 1 April 2007 and 31 January 2015.
exPOsures
Hypoglycaemic agents (glitazones, gliptins, 
metformin, sulphonylureas, insulin, and other) alone 
and in combination.
Main OutCOMe Measures
First recorded diagnoses of amputation, blindness, 
severe kidney failure, hyperglycaemia, and 
hypoglycaemia recorded on patients’ primary care, 
mortality, or hospital records. Cox models estimated 
hazard ratios for diabetes treatments adjusting for 
potential confounders.
results
21 308 (4.5%) and 32 533 (6.9%) patients received 
prescriptions for glitazones and gliptins during 
follow-up, respectively. Compared with non-use, 
glitazones were associated with a decreased risk of 
blindness (adjusted hazard ratio 0.71, 95% confidence 
interval 0.57 to 0.89; rate 14.4 per 10 000 person years 
of exposure) and an increased risk of hypoglycaemia 
(1.22, 1.10 to 1.37; 65.1); gliptins were associated with a 
decreased risk of hypoglycaemia (0.86, 0.77 to 0.96; 
45.8). Although the numbers of patients prescribed 
gliptin monotherapy or glitazones monotherapy were 
relatively low, there were significantly increased risks 
of severe kidney failure compared with metformin 
monotherapy (adjusted hazard ratio 2.55, 95% 
confidence interval 1.13 to 5.74). We found significantly 
lower risks of hyperglycaemia among patients 
prescribed dual therapy involving metformin with 
either gliptins (0.78, 0.62 to 0.97) or glitazones (0.60, 
0.45 to 0.80) compared with metformin monotherapy. 
Patients prescribed triple therapy with metformin, 
sulphonylureas, and either gliptins (adjusted hazard 
ratio 5.07, 95% confidence interval 4.28 to 6.00) or 
glitazones (6.32, 5.35 to 7.45) had significantly higher 
risks of hypoglycaemia than those prescribed 
metformin monotherapy, but these risks were similar 
to those involving dual therapy with metformin and 
sulphonylureas (6.03, 5.47 to 6.63). Patients 
prescribed triple therapy with metformin, 
sulphonylureas, and glitazones had a significantly 
reduced risk of blindness compared with metformin 
monotherapy (0.67, 0.48 to 0.94).
COnClusiOns
We have found lower risks of hyperglycaemia among 
patients prescribed dual therapy involving metformin 
with either gliptins or glitazones compared with 
metformin alone. Compared with metformin 
monotherapy, triple therapy with metformin, 
sulphonylureas, and either gliptins or glitazones was 
associated with an increased risk of hypoglycaemia, 
which was similar to the risk for dual therapy with 
metformin and sulphonylureas. Compared with 
metformin monotherapy, triple therapy with metformin, 
sulphonylureas, and glitazones was associated with a 
reduced risk of blindness. These results, while subject 
to residual confounding, could have implications for 
the prescribing of hypoglycaemic drugs.
Introduction
Type 2 diabetes is associated with increased risks of 
 macrovascular complications (such as heart failure and 
WhAT IS AlReAdy knoWn
Type 2 diabetes is associated with increased risks of microvascular complications 
(including lower limb amputation, blindness, kidney failure) and hypoglycaemic 
and hyperglycaemic attacks
Clinical trial evidence for glitazones and gliptins is largely based on surrogate 
endpoints (such as reduction of HbA1c) rather than hard clinical endpoints (such as 
reduced incidence of complications)
There is a need to quantify risks of clinical outcomes in large representative 
populations of patients with type 2 diabetes prescribed these drugs over longer 
periods of time
WhAT ThIS STudy AddS
Although the numbers of patients prescribed gliptin monotherapy or glitazone 
monotherapy were relatively low, we found an increased risk of severe kidney 
failure compared with metformin monotherapy despite adjustments for serum 
creatinine and other risk factors at baseline
We found reduced risks of hyperglycaemia among patients prescribed dual therapy 
of metformin with either gliptins or glitazones, compared with metformin 
monotherapy
Compared with metformin monotherapy, triple therapy with metformin, 
sulphonylureas, and either gliptins or glitazones was associated with an increased 
risk of hypoglycaemia; compared with metformin monotherapy, triple therapy with 
metformin, sulphonylureas, and glitazones was associated with a reduced risk of 
blindness
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cardiovascular disease), microvascular complications 
(including lower limb amputation, blindness, kidney 
failure), and hypoglycaemic and hyperglycaemic attacks. 
Higher levels of glycated haemoglobin (HbA1c) are asso-
ciated with higher risks of both microvascular and micro-
vascular complications.1  The UK Prospective Diabetes 
Study (UKPDS) showed a reduced risk of microvascular 
complications with intensive hypoglycaemic treatment, 
particularly with metformin, but no conclusive benefit 
for cardiovascular outcomes.2 3 Additional observational 
analyses of the UKPDS cohort suggested that any lower-
ing of HbA1c is likely to reduce risk of microvascular com-
plications as well as cardiovascular outcomes.1
Apart from the original UKPDS studies, clinical trial 
evidence for newer hypoglycaemic agents—such as gli-
tazones (thiazolidinediones) and gliptins—has been 
largely based on surrogate endpoints such as reduction 
of HbA1c rather than hard clinical endpoints such as 
increased survival rates or reduced incidence of compli-
cations. While the assumption that lowering HbA1c will 
result in a net clinical benefit seems plausible, evidence 
suggests that it is not always reliable. Phenformin, a 
biguanide, was withdrawn from the market in 1978 
because of concerns about increased risk of cardiovas-
cular events and lactic acidosis.4  In the United King-
dom, troglitazone (an insulin sensitising glitazone) was 
withdrawn from the market in 1997 a few months after 
its launch because of hepatotoxicity.5 The drug was 
withdrawn from the United States three years later.
Other newer hypoglycaemic agents have subse-
quently shown unexpected increases in cardiovascular 
endpoints.6-9 For example, rosiglitazone, another glita-
zone, was associated with an increased incidence of 
heart failure.6 This resulted in the drug’s withdrawal 
from Europe, India, New Zealand, and South Africa in 
2010-11, although it continues to be available in the 
USA, albeit with limitations. Uncertainty therefore 
remains over the longer term comparative clinical risks 
and benefits among patients prescribed diabetes drugs, 
particularly gliptins and glitazones alone and in combi-
nation with other treatments.10 11  Regulatory agencies 
have responded to this uncertainty, not by requiring 
evidence of direct clinical benefit but by requiring evi-
dence that new hypoglycaemic drugs are not associated 
with harmful increases in cardiovascular events.12 13 
This has led to industry funded, controversial non-infe-
riority trials such as the RECORD study, in which rosigl-
itazone was assumed to be non-inferior so long as the 
upper limit of the 95% confidence interval of the hazard 
ratio for cardiovascular disease was less than 1.20.14 15 
While the RECORD study confirmed an increased risk of 
heart failure with rosiglitazone, it was unable to rule 
out an increased risk of myocardial infarction.14
The lifelong nature of diabetes, together with the 
marked increase in its prevalence and the inclusion of 
prescribing recommendations in guidelines,16  are likely 
to lead to increases in the numbers of patients prescribed 
different diabetes drugs. Given the impracticability and 
ethical difficulties of head to head trials, there is a need to 
quantify risks of clinical outcomes in large representative 
populations of patients with type 2 diabetes prescribed 
these drugs over longer periods. This information can 
complement information from meta-analyses of clinical 
trials where available, although these sources can have 
publication bias, lack sufficient reporting of outcomes, 
and have insufficient duration of follow-up or power to 
make relevant comparisons for effects on clinical end-
points.11 17 Although the focus of attention for new dia-
betes drugs has shifted from HbA1c alone to include 
cardiovascular outcomes, relatively little clinical trial 
evidence has accrued as to whether the newer diabetes 
drugs increase or decrease risk of other diabetes com-
plications including lower limb amputation, blindness, 
kidney failure, serious hyperglycaemic or hypoglycae-
mic episodes, although these are the complications of 
particular importance to patients.18 There is also a lack 
of evidence on how these drugs are used, alone and in 
combination, in real world populations. This is import-
ant given that there are now a plethora of individual 
hypoglycaemic agents available from at least six differ-
ent drug classes.
We therefore carried out a cohort study using a large 
UK primary care database with linked general practice, 
mortality, and hospital admissions data. This study 
aimed to investigate the associations between different 
classes of diabetes drugs and the risks of microvascular 
complications (severe kidney failure, blindness, and 
amputation), and serious hyperglycaemic or hypogly-
caemic events. We were particularly interested in the 
risks associated with the newer agents, including glita-
zones and gliptins. In a separate analysis not included 
in this paper, we have compared the risks of heart fail-
ure, cardiovascular disease, and all cause mortality 
between different classes of diabetes drugs in patients 
with type 2 diabetes.
Methods
setting and data source
We did a population based open cohort study of 
patients in England aged 25-84 years with a diagnosis of 
type 2 diabetes. We used a large population of primary 
care patients derived from version 40 of the QResearch 
database (www.qresearch.org). QResearch is a continu-
ally updated, patient level, pseudonymised database 
with event level data extending back to 1989. QResearch 
currently includes clinical and demographic data from 
1243 general practices in England and two practices in 
Scotland covering a population of over 24 million 
patients, collected in the course of routine healthcare 
by general practitioners and associated staff.
The primary care data includes demographic infor-
mation, diagnoses, prescriptions, referrals, laboratory 
results, and clinical values. Diagnoses are recorded 
using the Read code classification.19 QResearch has 
been used for a wide range of clinical research includ-
ing the assessment of unintended effects of commonly 
prescribed medicines.20-25 The primary care data are 
linked at individual patient level to Hospital Episode 
Statistics, and mortality records from the Office for 
National Statistics (ONS). Hospital Episode Statistics 
provides details of all inpatient admissions in the UK’s 
health service since 1997, including primary and 
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 secondary causes coded by ICD-10 (international classi-
fication of diseases, 10th revision) and operations and 
interventions coded by OPCS-4 (OPCS classification of 
interventions and procedures version 4). ONS provides 
details of all deaths in England with primary and under-
lying causes, also coded using ICD-10. Patient records 
are linked using a project specific pseudonymised NHS 
number, which is valid and complete for 99.8% of pri-
mary care patients, 99.9% for ONS mortality records, 
and 98% for hospital admissions records.1
inclusion and exclusion criteria
We included all QResearch practices in England who 
had been using the Egton Medical Information Systems 
(EMIS) computer system for at least a year. We initially 
identified an open cohort of patients aged 25-84 years 
registered with eligible practices between 1 April 2007 
and 31 January 2015. We chose this study period because 
both pioglitazone and gliptins were available in the UK 
for the full study period. We then selected patients with 
diabetes if they had a Read code for diabetes or more 
than one prescription for a hypoglycaemic drug.
We excluded patients as having type 1 diabetes if they 
had been diagnosed under the age of 35 years and pre-
scribed insulin.26 We also excluded patients without a 
postcode related deprivation score. We determined an 
entry date to the cohort for each patient, which was the 
latest of the following: date of diagnosis of diabetes, 
25th birthday, date of registration with the practice plus 
one year, date on which the practice computer system 
was installed plus one year, and the beginning of the 
study period. We excluded patients with an existing 
diagnosis of an outcome of interest at the study entry 
date from the analysis of that outcome.
We used an incident user design for patients pre-
scribed glitazones, gliptins (our main exposures of inter-
est), or insulin to reduce bias.27  We defined incident 
users as patients without a prescription for these drugs 
in the 12 months before the study entry date as in other 
studies,28 and we excluded people who had received any 
of these drugs in the previous 12 months. We included 
prevalent users of metformin or sulphonylureas in the 
study cohort, because glitazones and gliptins are usu-
ally prescribed after monotherapy with metformin or 
sulphonylureas. Exclusion of prevalent users of met-
formin or sulphonylureas would have substantially 
reduced the numbers of new users of glitazones and 
gliptins, which were our main exposures of interest.
Outcomes
We had five primary outcomes based on diagnoses and 
procedures recorded either in the patient’s primary care 
record or in their linked hospital record or mortality 
record during follow-up:
•	 Lower limb amputation—including hindquarter, 
above knee, or below knee amputation
•	 Blindness—including blindness in one or both eyes, 
registered blindness, and severe visual impairment
•	 Severe kidney failure—including kidney dialysis, 
 kidney transplant, chronic kidney disease stage 5
•	 Hyperglycaemia—including hyperosmolar hypergly-
caemic coma, diabetic ketoacidosis
•	 Hypoglycaemia—including spontaneous, reactive, 
drug induced hypoglycaemia events requiring para-
medic or hospital admission or resulting in death
We used Read codes to identify recorded diagnoses 
from the primary care records. We used ICD-10 clinical 
codes and OPCS-4 procedure codes to identify incident 
cases from hospital and ONS mortality records. Web 
appendix 1 lists the clinical codes used to identify each 
outcome. We used the earliest recorded date from any of 
the three data sources as the index date for the diagno-
sis for each outcome. Patients were censored at the ear-
liest date of the first recorded diagnosis of the outcome 
of interest, death, deregistration with the practice, last 
upload of computerised data, or the study end date 
(31 January 2015).
exposure data
Our primary exposures of interest were new use of 
gliptins and new use of glitazones during the study 
period. We extracted details of all individual 
 prescriptions for all types of hypoglycaemics for each 
patient including the prescription date and the type. We 
partitioned the follow-up time into different treatment 
periods, where each period corresponded to treatment 
with a particular type or combination of hypoglycaemic 
drugs, or could be a period of no treatment with any 
hypoglycaemic drugs. If the patient changed to a differ-
ent type of treatment or to a different combination of 
treatments, we classified that as a separate treatment 
period. For example, consider a patient who was pre-
scribed metformin alone on cohort entry for 12 months, 
then was prescribed both glitazones and metformin for 
another 24 months, and then had a treatment free 
period for six months until they were censored. This 
patient would have three treatment periods (metformin 
only for 12 months, metformin and glitazones for 24 
months, and no treatment for six months).
We determined the duration of each treatment period 
by calculating the number of days between the earliest 
issue date and the latest issue date for the type of treat-
ment prescribed. If another treatment was added before 
the initial treatment was stopped, the treatment period 
on the initial treatment alone was the number of days 
between the earliest issue date for the initial treatment 
and the earliest issue date for the next treatment. We 
added 90 days to the last prescription date as an esti-
mate of the date on which the patient stopped treat-
ment (the stop date). We made this assumption to allow 
for events that occur during a withdrawal period to be 
attributed to the medication rather than counting as 
unexposed time.
For the analysis, we used six binary exposure vari-
ables for each treatment period to indicate treatment 
with any of the diabetes drugs grouped into six drug 
classes: glitazones, gliptins, metformin, sulphony-
lureas, insulin, and other oral hypoglycaemic drugs 
(including α-glucosidase inhibitors, glinides, sodi-
um-glucose cotransporter 2 inhibitors, guar). These 
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drug classes were not split into individual drugs in the 
analyses. This exposure classification allowed for 
patients to be on different combinations of these drugs 
during a treatment period. To further assess associa-
tions for different specific treatment combinations 
(such as dual therapy with metformin and glitazones), 
we also categorised treatments during each treatment 
period into one categorical variable with 21 mutually 
exclusive categories. These mutually exclusive catego-
ries included a no current treatment group and 20 cate-
gories for mono, dual, and triple combinations of drugs.
Confounding variables
We considered confounding variables that were likely 
to be associated with the risk of the diabetes complica-
tions according to the established literature28-32 or with 
the likelihood of receiving treatment for different hypo-
glycaemic drugs. These included:
•	 Age at study entry
•	 Sex
•	 Number of years since diagnosis of diabetes (catego-
rised as <1, 1-3, 4-6, 7-10, ≥11)32
•	 Calendar year
•	 Smoking status (non-smoker, ex-smoker, light 
smoker (1-9 cigarettes/day), moderate smoker (10-19 
cigarettes/day), heavy smoker (≥20 cigarettes/day), 
not recorded)
•	 Ethnic group (categorised as white/not recorded, 
Indian, Pakistani, Bangladeshi, other Asian, black 
African, black Caribbean, Chinese, other including 
mixed)29
•	 Townsend deprivation score
•	 Complications (severe kidney failure,32 one or more 
episodes of hyperglycaemia, one or more episodes of 
hypoglycaemia, amputation, blindness—other than 
where the complication was the outcome of interest 
in which case patients with an existing diagnosis of 
the outcome of interest at the study entry date were 
excluded)
•	 Comorbidities (cardiovascular disease,32  heart fail-
ure, peripheral vascular disease, valvular heart dis-
ease, chronic kidney disease, atrial fibrillation,29 
hypertension,29  rheumatoid arthritis29)
•	 Prescription drugs (statins, aspirin, anticoagulants, 
thiazides, angiotensin converting enzyme (ACE) 
inhibitors/angiotensin blockers, calcium channel 
blockers)
•	 Clinical values (body mass index,32  cholesterol:high 
density lipoprotein (HDL) ratio,29  systolic blood pres-
sure,29 serum creatinine, HbA1c1 32).
We evaluated confounders at the start of each treatment 
period for comorbidities, other complications, other 
prescribed medications, smoking status, and clinical 
values. For comorbidities and other complications, we 
identified whether patients had a diagnosis recorded 
before the relevant treatment period. For prescribed 
medications, we defined patients as treated at the start 
of the relevant period of diabetes drug treatment if they 
had at least two prescriptions for the other type of drug, 
including one in the 28 days before the treatment period 
and one after the start date. For smoking status and 
continuous variables (systolic blood pressure, body 
mass index, creatinine, cholesterol:HDL ratio, and 
HbA1c), we used the most recent recorded value imme-
diately before the relevant treatment period. We catego-
rised duration of diabetes as this had a highly skewed 
distribution, with a substantial proportion of newly 
diagnosed patients due to the open cohort design.
analysis
We used Cox proportional hazards models to assess the 
associations between the six different classes of hypogly-
caemic drugs and risk of each of our outcomes, adjusting 
for potential confounding variables. We used the Cox 
model for analysis rather than a competing risks analy-
sis, because it is considered more appropriate for aetio-
logical analyses such as this study whereas competing 
risks analyses tend to be most useful for prediction mod-
elling or estimating absolute risks.33-35 To account for 
patients starting and stopping different treatments and 
changing between treatments, we treated hypoglycaemic 
exposures as time varying  exposures.
In the analysis, we calculated unadjusted and 
adjusted hazard ratios for the six different diabetes 
drug classes (each as a binary variable indicating use 
or no use) with adjustment for the confounding vari-
ables and the other classes of hypoglycaemic drugs. 
We also calculated unadjusted and adjusted hazard 
ratios for the mutually exclusive treatment combina-
tions comparing each treatment category with no cur-
rent treatment and also with metformin alone. To 
determine whether significant differences existed 
between classes or individual drugs, we carried out 
Wald’s tests. We tested for interactions between the six 
different drug classes and age, sex, HbA1c, and body 
mass index.
We used multiple imputation with chained equations 
to replace missing values for continuous values and 
smoking status, and used these values in our main 
analyses.36-38 We did this for each study outcome and 
included the censoring indicator for the outcome, the 
log of survival time, all the confounding variables, and 
the diabetes drug treatment variables in the imputation 
model. We log-transformed body mass index, HbA1c, 
creatinine, cholesterol, and HDL cholesterol before 
imputation, because they had skewed distributions. We 
carried out five imputations and combined results using 
Rubin’s rules.
To evaluate the robustness of our results and assess 
the effect of confounding variables, we added the con-
founding variables to our model in blocks and com-
pared the adjusted hazard ratios. We assessed four 
models:
•	 Model A: diabetes drug classes adjusted for age, sex, 
ethnicity, deprivation, calendar year, duration of dia-
betes plus other diabetes drugs
•	 Model B: model A plus comorbidities (hypertension, 
cardiovascular disease, atrial fibrillation, chronic 
renal disease, rheumatoid arthritis, valvular heart 
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disease, peripheral vascular disease) plus existing 
complications (history of hypoglycaemia, hypergly-
caemia, amputation, severe kidney failure, blind-
ness) plus use of other drugs (statins, aspirin, 
anticoagulants, diuretics, ACE inhibitors/angiotensin 
blockers, β blockers, calcium channel blockers)
•	 Model C (primary analysis model): model B plus clin-
ical values (body mass index, cholesterol:HDL ratio, 
systolic blood pressure, serum creatinine, HbA1c)
•	 Model D: model C plus interaction terms
We also carried out a sensitivity analysis (model E) by 
excluding prevalent users of sulphonylureas from the 
study cohort so that the hazard ratios for sulphony-
lureas are based on incident users, and we refitted the 
primary analysis model (model C).
We included all the eligible patients in the database 
to maximise the power and also generalisability of the 
results. We used a P value less than 0.01 (two tailed) to 
determine statistical significance. Hazard ratios calcu-
lated as at least 1.10 or calculated as 0.90 or lower were 
considered as clinically important. We used Stata (ver-
sion 13.1) for all analyses.
Patient involvement
Patients were not involved in setting the research ques-
tion, the outcome measures, the design, or implemen-
tation of the study. Patient representatives from the 
QResearch Advisory Board have written the information 
for patients on the QResearch website about the use of 
the database for research. They have also advised on 
dissemination including the use of lay summaries 
describing the research and its results.
Results
Overall study population
Overall, 1243 QResearch practices in England met the 
inclusion criteria. We identified a cohort of 601 405 
patients aged 25-84 years with diabetes (fig 1 ). We 
sequentially excluded 31 224 (5.2%) patients with type 1 
diabetes, 748 (0.1%) without a Townsend deprivation 
score, and 99 745 (16.6%) prescribed glitazones, 
gliptins, or insulin in the 12 months before the study 
entry date. These exclusions left 469 688 patients with 
type 2 diabetes in the study cohort. Figure 1 also shows 
the numbers of patients with each outcome at baseline 
who were excluded from the analysis of that outcome as 
well as the numbers of incident outcomes observed 
during follow-up.
baseline characteristics
In total, 274 324 (58.4%) of the patients in the study 
cohort received prescriptions for one or more diabetes 
drugs during follow-up. 21 308 (4.5%) were prescribed 
glitazones, 32 533 (6.9%) prescribed gliptins, 256 024 
(54.5%) prescribed metformin, 134 570 (28.7%) 
 prescribed sulphonylureas, 19 791 (4.2%) prescribed 
insulin, and 12 062 (2.6%) prescribed other oral hypo-
glycaemic agents. Of those patients receiving 
 prescriptions for glitazones, 19 051 (89.4%) received 
pioglitazone with the remainder receiving rosiglita-
zone.
Table 1 shows the characteristics of patients pre-
scribed each of the six classes of diabetes drugs during 
follow-up based on the last recorded value before the 
medication was first prescribed (or at study entry for 
patients already prescribed sulphonylureas, met-
formin, or other hypoglycaemics at baseline). The 
groups were similar for most characteristics except for 
increased levels of comorbidities other than hyperten-
sion in patients prescribed insulin, and reduced levels 
of prescriptions for statins and aspirin in patients pre-
scribed metformin compared with the other drugs.
Table 2 shows levels of recording and mean values for 
HbA1c, body mass index, cholesterol:HDL ratio, systolic 
blood pressure, and serum creatinine before the start of 
treatment (or at study entry for patients already pre-
scribed sulphonylureas, metformin, or other hypoglycae-
mics at baseline). Highest levels of recording were for 
HbA1c, which were in excess of 97% for all six drug groups. 
Lowest levels of recording were for cholesterol:HDL 
Patients aged 25-84 years with diabetes registered in 1998-2015 (n=601 405)
Patients with type 2 diabetes (n=570 181)
Patients with type 2 diabetes with Townsend score recorded (n=569 433)
Patients with type 2 diabetes  excluding prevalent users of insulin, gliptins, or glitazone (n=469 688)
Patients with blindness at
baseline excluded (n=7308)
Patients with incident
blindness (n=4028)
Patients with amputation at
baseline excluded (n=2584)
Patients with incident
amputation (n=2308)
Patients with kidney disease
at baseline excluded (n=2333)
Patients with incident severe
kidney disease (n=2524)
Patients with hyperglycaemia at
baseline excluded (n=118 775)
Patients with incident
hyperglycaemia (n=13 039)
Patients with hypoglycaemia
at baseline excluded (n=5370)
Patients with incident
hypoglycaemia (n=7286)
Patients with type 2 diabetes without Townsend score (n=748)
Patients with type 1 diabetes (n=31 224)
Patients with type 2 diabetes who are prevalent
users of gliptins or glitazones or insulin (n=99 745)
Fig 1 | Flow of patients through study
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ratios, which were above 84% for all drug groups. Over-
all, at least 82% of patients had complete data for all 
five clinical values across all drug groups. Apart from 
higher mean levels of HbA1c in patients before exposure 
to insulin and the other hypoglycaemic groups, and 
higher levels of creatinine among those prescribed sul-
phonylureas or insulin, mean values were similar 
across the six groups. Web table 1 shows mean values 
before starting the 20 different treatment combinations. 
The mean values for HbA1c tended to be higher for 
patients starting triple therapy (as high values of HbA1c 
will tend to trigger changes in therapy).
risks associated with use of each medication group
Table 3  shows the number of incident cases of each out-
come for patients during periods of exposure to each of 
table 1 | Characteristics of patients with type 2 diabetes
glitazones gliptins Metformin sulphonylureas insulin
Other hypo­
glycaemic agents
Total No of patients exposed 21 308 32 533 256 024 134 570 19 791 12 062
Mean age at study entry (SD) 63.0 (11.9) 63.3 (12.1) 64.6 (13.1) 66.2 (12.9) 64.5 (12.7) 60.0 (11.9)
Mean Townsend score (SD) 0.4 (3.5) 0.5 (3.5) 0.6 (3.6) 0.6 (3.6) 0.5 (3.6) 0.8 (3.6)
Male 12 658 (59.4) 18 871 (58.0) 146 690 (57.3) 79 284 (58.9) 11 499 (58.1) 6509 (54.0)
Time since diagnosis of diabetes
 Newly diagnosed 4412 (20.7) 10 166 (31.2) 100 690 (39.3) 33 363 (24.8) 6223 (31.4) 2895 (24.0)
 1-3 years ago 5996 (28.1) 8590 (26.4) 62 951 (24.6) 32 604 (24.2) 3999 (20.2) 3115 (25.8)
 4-6 years ago 5033 (23.6) 6561 (20.2) 43 477 (17.0) 28 187 (20.9) 3628 (18.3) 2570 (21.3)
 7-10 years ago 3389 (15.9) 4288 (13.2) 28 054 (11.0) 21 768 (16.2) 3128 (15.8) 1874 (15.5)
 >10 years ago 2478 (11.6) 2928 (9.0) 20 852 (8.1) 18 648 (13.9) 2813 (14.2) 1608 (13.3)
Ethnicity recorded 19 130 (89.8) 29 396 (90.4) 228 962 (89.4) 119 507 (88.8) 17 264 (87.2) 10 947 (90.8)
 White or not recorded 17 112 (80.3) 26 104 (80.2) 204 915 (80.0) 107 537 (79.9) 17 001 (85.9) 10 135 (84.0)
 Indian 997 (4.7) 1662 (5.1) 11 732 (4.6) 5978 (4.4) 476 (2.4) 420 (3.5)
 Pakistani 811 (3.8) 1132 (3.5) 7425 (2.9) 3972 (3.0) 389 (2.0) 290 (2.4)
 Bangladeshi 586 (2.8) 713 (2.2) 7282 (2.8) 3980 (3.0) 370 (1.9) 374 (3.1)
 Other Asian 476 (2.2) 720 (2.2) 5873 (2.3) 2947 (2.2) 234 (1.2) 164 (1.4)
 Caribbean 473 (2.2) 795 (2.4) 6376 (2.5) 3700 (2.7) 549 (2.8) 278 (2.3)
 Black African 392 (1.8) 676 (2.1) 5715 (2.2) 2977 (2.2) 350 (1.8) 161 (1.3)
 Chinese 84 (0.4) 95 (0.3) 983 (0.4) 513 (0.4) 36 (0.2) 34 (0.3)
 Other 377 (1.8) 636 (2.0) 5723 (2.2) 2966 (2.2) 386 (2.0) 206 (1.7)
Smoking status recorded 21 215 (99.6) 32 399 (99.6) 255 186 (99.7) 134 080 (99.6) 19 569 (98.9) 12 003 (99.5)
 Non-smoker 11 374 (53.4) 17 116 (52.6) 132 634 (51.8) 69 849 (51.9) 9393 (47.5) 6126 (50.8)
 Ex-smoker 6252 (29.3) 9725 (29.9) 78 935 (30.8) 41 438 (30.8) 6142 (31.0) 3726 (30.9)
 Light smoker 2170 (10.2) 3358 (10.3) 25 678 (10.0) 13 846 (10.3) 2413 (12.2) 1252 (10.4)
 Moderate smoker 730 (3.4) 1121 (3.4) 9395 (3.7) 4661 (3.5) 832 (4.2) 441 (3.7)
 Heavy smoker 689 (3.2) 1079 (3.3) 8544 (3.3) 4286 (3.2) 789 (4.0) 458 (3.8)
Comorbidities
 Cardiovascular disease 2962 (13.9) 5325 (16.4) 48 066 (18.8) 28 895 (21.5) 4596 (23.2) 1992 (16.5)
 Heart failure 302 (1.4) 737 (2.3) 6943 (2.7) 5069 (3.8) 960 (4.9) 374 (3.1)
 Peripheral vascular disease 1008 (4.7) 1576 (4.8) 12 458 (4.9) 8467 (6.3) 1519 (7.7) 544 (4.5)
 Valvular heart disease 379 (1.8) 914 (2.8) 7378 (2.9) 4606 (3.4) 765 (3.9) 292 (2.4)
 Hypertension 12 520 (58.8) 19 293 (59.3) 150 219 (58.7) 80 776 (60.0) 11 117 (56.2) 7310 (60.6)
 Atrial fibrillation 929 (4.4) 1980 (6.1) 17 327 (6.8) 10 574 (7.9) 1890 (9.5) 657 (5.4)
 Chronic kidney disease 388 (1.8) 593 (1.8) 3067 (1.2) 4183 (3.1) 1165 (5.9) 224 (1.9)
 Rheumatoid arthritis 719 (3.4) 1237 (3.8) 9718 (3.8) 5382 (4.0) 842 (4.3) 460 (3.8)
Prior complications
 Existing severe kidney failure 54 (0.3) 74 (0.2) 509 (0.2) 825 (0.6) 213 (1.1) 36 (0.3)
 Existing blindness 260 (1.2) 383 (1.2) 3715 (1.5) 2404 (1.8) 360 (1.8) 170 (1.4)
 Existing amputation 85 (0.4) 125 (0.4) 1239 (0.5) 894 (0.7) 161 (0.8) 65 (0.5)
 At least one previous episode of 
hypoglycaemia
288 (1.4) 286 (0.9) 2247 (0.9) 1946 (1.4) 337 (1.7) 215 (1.8)
 At least one previous episode of 
hyperglycaemia
7921 (37.2) 10 054 (30.9) 68 839 (26.9) 46 341 (34.4) 7279 (36.8) 3914 (32.4)
Other medications
 Anticoagulants 642 (3.0) 1419 (4.4) 9409 (3.7) 5989 (4.5) 1344 (6.8) 540 (4.5)
 Thiazides 3444 (16.2) 4346 (13.4) 31 291 (12.2) 16 972 (12.6) 2386 (12.1) 1844 (15.3)
 ACE inhibitors 9318 (43.7) 12 939 (39.8) 83 847 (32.7) 48 960 (36.4) 7750 (39.2) 5362 (44.5)
 Angiotension 2 blockers 3399 (16.0) 4895 (15.0) 28 629 (11.2) 16 976 (12.6) 2633 (13.3) 2088 (17.3)
 Calcium channel blockers 5613 (26.3) 8105 (24.9) 55 674 (21.7) 32 141 (23.9) 5034 (25.4) 3328 (27.6)
 Statins 15 512 (72.8) 21 383 (65.7) 137 574 (53.7) 77 865 (57.9) 12 640 (63.9) 8451 (70.1)
 Aspirin 7890 (37.0) 9684 (29.8) 68 013 (26.6) 41 647 (30.9) 7057 (35.7) 4096 (34.0)
Data are no (%) of patients unless stated otherwise. Values represent those recorded before starting treatment or at study entry for prevalent users. Treatment groups not mutually exclusive. 
ACE=angiotension converting enzyme; SD=standard deviation.
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table 2 | recorded clinical values for patients before starting diabetes medication or at study entry for prevalent users
glitazones gliptins Metformin sulphonylureas insulin
Other hypo­
glycaemic agents
Total patients exposed 21 308 32 533 256 024 134 570 19 791 12 062
No (%) of patients with values recorded
 HbA1c 21 251 (99.7) 32 474 (99.8) 253 219 (98.9) 133 170 (99.0) 19 255 (97.3) 12 022 (99.7)
 Body mass index 21 120 (99.1) 32 224 (99.1) 252 290 (98.5) 132 477 (98.4) 19 436 (98.2) 11 749 (97.4)
 Cholesterol:HDL ratio 18 264 (85.7) 29 307 (90.1) 224 504 (87.7) 115 991 (86.2) 16 723 (84.5) 10 619 (88.0)
 Systolic blood pressure 21 306 (100.0) 32 529 (100.0) 255 892 (99.9) 134 487 (99.9) 19 765 (99.9) 12 057 (100.0)
 Creatinine 21 288 (99.9) 32 509 (99.9) 255 381 (99.7) 134 244 (99.8) 19 655 (99.3) 12 044 (99.9)
 All above values recorded 18 097 (84.9) 29 010 (89.2) 220 119 (86.0) 113 843 (84.6) 16 270 (82.2) 10 340 (85.7)
Mean values (SD) recorded
 HbA1c (mmol/mol) 66.8 (18.9) 68.4 (18.4) 61.4 (18.7) 64.9 (19.9) 75.4 (22.7) 70.9 (19.6)
 Body mass index 31.7 (6.0) 31.7 (5.9) 30.6 (5.9) 30.1 (5.8) 30.2 (6.1) 34.1 (6.6)
 Cholesterol:HDL ratio 3.8 (1.3) 3.9 (1.3) 3.8 (1.3) 3.8 (1.3) 4.0 (1.4) 4.0 (1.3)
 Systolic blood pressure (mm Hg) 133.1 (14.8) 132.3 (14.7) 132.5 (15.3) 132.8 (15.9) 131.7 (16.9) 132.5 (14.9)
 Creatinine (μmol/L) 87.1 (33.7) 84.9 (33.3) 84.8 (30.1) 92.1 (47.7) 99.3 (62.0) 83.5 (34.6)
Treatment groups not mutually exclusive. HDL=high density lipoprotein; SD=standard deviation.
table 3 | number of incident events, person years, rates, and adjusted hazard ratios for each study outcome by use of 
diabetes drug
study outcome/
diabetes drug group no of events no of person years
rate per 10 000 person 
years of exposure
adjusted hazard 
ratios (95% Ci)*
blindness
Glitazones 79 54 981 14.4 0.71 (0.57 to 0.89)
Gliptins 117 70 197 16.7 0.83 (0.69 to 1.01)
Metformin 2021 1 045 943 19.3 0.70 (0.66 to 0.75)
Sulphonylureas 1220 494 418 24.7 0.96 (0.89 to 1.04)
Insulin 202 56 153 36.0 1.48 (1.28 to 1.72)
Other hypoglycaemic agents 52 27 715 18.8 0.86 (0.65 to 1.13)
Hyperglycaemia
Glitazones 180 32 966 54.6 0.88 (0.76 to 1.02)
Gliptins 265 46 686 56.8 0.93 (0.82 to 1.05)
Metformin 5368 712 777 75.3 0.65 (0.62 to 0.67)
Sulphonylureas 2216 297 347 74.5 0.99 (0.94 to 1.04)
Insulin 415 32 321 128.4 1.69 (1.53 to 1.87)
Other hypoglycaemic agents 130 17 531 74.2 0.95 (0.80 to 1.14)
Hypoglycaemia
Glitazones 355 54 507 65.1 1.22 (1.10 to 1.37)
Gliptins 319 69 719 45.8 0.86 (0.77 to 0.96)
Metformin 3905 1 047 042 37.3 0.58 (0.55 to 0.61)
Sulphonylureas 4064 491 712 82.7 2.93 (2.78 to 3.09)
Insulin 1133 53 882 210.3 4.57 (4.27 to 4.89)
Other hypoglycaemic agents 176 27 313 64.4 1.07 (0.92 to 1.25)
amputation
Glitazones 62 55 551 11.2 0.77 (0.60 to 1.00)
Gliptins 99 71 007 13.9 0.88 (0.71 to 1.08)
Metformin 1195 1 059 266 11.3 0.70 (0.64 to 0.77)
Sulphonylureas 819 502 028 16.3 1.05 (0.95 to 1.15)
Insulin 199 56 798 35.0 1.64 (1.41 to 1.91)
Other hypoglycaemic agents 45 28 028 16.1 0.93 (0.69 to 1.25)
Kidney failure
Glitazones 54 55 677 9.7 1.05 (0.80 to 1.38)
Gliptins 64 71 251 9.0 0.99 (0.77 to 1.27)
Metformin 562 1 064 018 5.3 0.41 (0.37 to 0.46)
Sulphonylureas 881 502 691 17.5 1.21 (1.10 to 1.33)
Insulin 235 56 573 41.5 1.45 (1.25 to 1.68)
Other hypoglycaemic agents 35 28 166 12.4 0.80 (0.56 to 1.14)
Hazard ratio for each diabetes drug group is compared with patients not prescribed that particular medication.
*Hazard ratios adjusted for: sex; age; calendar year; duration since diagnosis of diabetes (five levels); ethnicity (nine levels); Townsend deprivation score; 
smoking status (five levels); use of anticoagulants, thiazides, ACE inhibitors, angiotensin 2 blockers; calcium channel blockers; statins; aspirin; existing 
complications (blindness, hyperglycaemia, hypoglycaemia, amputation, severe kidney failure); hypertension; cardiovascular disease; atrial fibrillation; 
chronic renal disease; rheumatoid arthritis; valvular heart disease; peripheral vascular disease; body mass index; systolic blood pressure; HbA1c; serum 
creatinine; cholesterol:high density lipoprotein ratio. Hazard ratios also mutually adjusted for use of each of the other diabetes drug classes.
doi: 10.1136/bmj.i1450 | BMJ 2016;352:i1450 | the bmj
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the six treatment classes during follow-up. The treatment 
classes in table 3  are not mutually exclusive—for 
 example, the row for glitazones includes any use of glita-
zones, whether as monotherapy, dual therapy, or triple 
therapy. Similarly, the adjusted hazard ratios for model C 
shown in table 3 give an overall risk for the use of each 
drug group compared with non-use of that drug group, 
having adjusted for use of other diabetes drugs and the 
potential confounders listed in the footnote.
For our main exposures of interest, we found:
•	 Compared with non-use, glitazones were signifi-
cantly associated with a 29% decreased risk of blind-
ness; and a 22% increased risk of hypoglycaemia.
•	 Compared with non-use, gliptins were significantly 
associated with a 14% decreased risk of hypogly-
caemia.
In addition for the other diabetes drug groups, we 
found:
•	 Compared with non-use, metformin was associated 
with a significantly decreased risk of all five out-
comes: reductions in risk of 30% for blindness, 35% 
for hyperglycaemia, 42% for hypoglycaemia, 30% for 
amputation, and 59% for severe kidney failure.
•	 Compared with non-use, sulphonylureas were sig-
nificantly associated with a 193% increased risk of 
hypoglycaemia and a 21% increased risk of severe 
kidney failure.
•	 Compared with non-use, insulin was associated with 
significantly increased risks of all outcomes: 
increases of 48% for blindness, 69% for hyperglycae-
mia, 357% for hypoglycaemia, 64% for amputation, 
and 45% for severe kidney failure.
•	 Compared with non-use, the other hypoglycaemic 
group was not associated with a significant increase 
or decrease in risk of any complication though the 
person years of exposure for this group were lower 
than the other groups in the analysis.
The only significant interaction involving glitazones or 
gliptins was between glitazones and age for hypogly-
caemia (web table 2; model D), where the increased risk 
of hypoglycaemia associated with glitazone use became 
more marked with increasing age.
Web table 2 also shows the results from analyses 
 adding confounders in separate blocks (models A and 
B). Generally, inclusion of comorbidities and existing 
complications in the model (model B) tended to 
slightly reduce hazard ratios (compared with model 
A), which was most marked for sulphonylureas and 
insulin. Further inclusion of clinical values (table 3; 
model C) only resulted in small changes to the hazard 
ratios with the exception of severe kidney failure 
which had some larger increases, for example, from 
0.74 (95% confidence interval 0.56 to 0.97) to 1.05 (0.80 
to 1.38) for glitazones.
The sensitivity analysis excluding the 73 445 prevalent 
users of sulphonylureas at study entry showed some 
increases in adjusted hazard ratios for sulphonylureas 
compared with model C (web table 2; model E), with 
the largest increase for hypoglycaemia (increase from 
2.93 to 3.99).
risks associated with different treatment 
combinations
Table 4 shows a more detailed breakdown of 21 mutu-
ally exclusive treatment categories, including a “no cur-
rent treatment group” that included 0.7 million person 
years free of any hypoglycaemic medication. The table 
shows the number of events for each clinical outcome 
for each of the treatment categories.
Table 5  shows the corresponding adjusted hazard 
ratios for each treatment group category compared with 
monotherapy with metformin. For glitazones, we saw a 
significant increase in the risk of severe kidney failure 
for monotherapy with glitazones (155% increase), but 
no significant associations between glitazone 
 monotherapy and risk of any other complications, com-
pared with monotherapy with metformin. However, 
glitazone monotherapy was relatively uncommon (table 
4). Dual therapy with glitazones and metformin was 
associated with a significantly decreased risk of hyper-
glycaemia (reduction of 40%). Dual therapy with glita-
zones and sulphonylureas was associated with a 93% 
increased risk of hyperglycaemia, a 106% increased risk 
of amputation, a 114% increased risk of severe kidney 
failure, and more than a 13-fold increased risk of hypo-
glycaemia compared with metformin monotherapy. Tri-
ple therapy with metformin, sulphonylureas, and 
glitazones was associated with a decreased risk of 
blindness (33% reduction) and more than a sixfold 
increased risk of hypoglycaemia.
 Gliptin monotherapy was associated with more than 
a threefold increased risk of severe kidney failure com-
pared with monotherapy with metformin (adjusted haz-
ard ratio 3.52; 95% confidence interval 2.04 to 6.07), but 
there were no other significant associations although 
gliptin monotherapy was relatively uncommon (table 
4). Dual therapy with gliptins and metformin was asso-
ciated with a 22% decreased risk of hyperglycaemia. 
Dual therapy with gliptins and sulphonylureas was 
associated with nearly a sixfold increased risk of hypo-
glycaemia and more than a threefold increased risk of 
severe kidney failure. Triple therapy with gliptins, met-
formin and sulphonylureas was associated with a five-
fold increased risk of hypoglycaemia (5.07; 4.28 to 6.00). 
The increased risks of hypoglycaemia in patients pre-
scribed triple therapy with metformin, sulphonylureas, 
and either gliptins or glitazones were similar to those 
involving dual therapy with metformin and sulphony-
lureas (adjusted hazard ratio 6.03, 95% confidence 
interval 5.47 to 6.63).
Web table 3 shows the results for the different treat-
ment combinations compared with periods of no hypo-
glycaemic treatment. Web table 4 shows the results for 
the different treatment combinations compared with no 
treatment having dropped prevalent users of sulphony-
lureas at study entry. Overall, the adjusted hazard ratios 
for glitazones and gliptins were similar to those in web 
table 3 except confidence intervals were wider due to 
the bmj | BMJ 2016;352:i1450 | doi: 10.1136/bmj.i1450
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reduced numbers and there were fewer significant asso-
ciations.
discussion
Key findings
This cohort study has found clinically important differ-
ences between different hypoglycaemic drugs (alone 
and in combination) and the risk of five key outcomes 
(blindness, amputation, severe kidney failure, hyper-
glycaemia, and hypoglycaemia) in patients with type 2 
diabetes. Our study aimed to look at a range of compli-
cations in relation to drug treatment whereas many pre-
vious studies have either been clinical trials that have 
had limited sample sizes and durations; or observa-
tional studies that have focused on one particular drug 
or drug combination.
Overall, we found a reduced risk of blindness and an 
increased risk of hypoglycaemia associated with glita-
zones, and a reduced risk of hypoglycaemia associated 
with gliptins. A more detailed analysis according to 
combinations of treatments showed some differences 
according to whether glitazones and gliptins were 
 prescribed as monotherapy or dual or triple therapy 
with other agents. Our results indicate that gliptins and 
glitazones are associated with an increased risk of kid-
ney failure compared with metformin monotherapy only 
when used as monotherapy or in combination with sul-
phonylureas, despite adjustments for serum creatinine 
and other risk factors at baseline. However, the risks 
when used in combination with sulphonylureas are sim-
ilar to the risk with sulphonylureas monotherapy. This 
suggests either a drug-drug interaction in the dual ther-
apy, where the other drug used has a modifying effect on 
risk, or indication bias when these drugs are used as 
monotherapy since this combination is mainly likely to 
be in patients with contraindications to metformin, as 
recommended in guidelines. For example, the British 
National Formulary indicates that metformin should be 
avoided in patients with significant renal impairment 
owing to increased risk of lactic acidosis.
Although the numbers prescribed gliptin monother-
apy or glitazones monotherapy were relatively low, the 
findings appear consistent with other reports of safety 
of the renally excreted gliptins.39  But other data in rela-
tion to this outcome are limited. Our finding for glita-
zones is consistent with increased risks of incident 
chronic kidney disease reported in a observational 
study of almost 4000 users of pioglitazone followed 
between 2003 and 2009 in Taiwan.40  Although pioglita-
zone is extensively metabolised in the liver,41  pioglita-
zone is also known to increase fluid and sodium 
retention particularly in patents with renal impair-
ment.42  This, together with the concerns regarding pos-
sible increased risk of bladder cancer, has led to the 
withdrawal of pioglitazone use in France and Germany 
and caution regarding its use in Switzerland.43
Dual treatment combinations for glitazones or 
gliptins with metformin showed reduced risks of hyper-
glycaemia compared with metformin monotherapy and 
no significant increases in risk for the other outcomes. 
Triple therapy involving metformin, sulphonylureas, t
ab
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and glitazones was associated with a significantly 
decreased risk of blindness, and an increased risk of 
hypoglycaemia. Similarly, triple therapy of metformin, 
sulphonylureas, and gliptins was associated with a sig-
nificantly increased risk of hypoglycaemia.
Overall, triple therapy involving gliptins or glita-
zones does not appear to have consistent measurable 
advantages compared with dual therapy or monother-
apy with metformin for these five clinical outcomes. 
This triple combination also showed substantially 
increased risks of hypoglycaemia when compared 
against metformin monotherapy although risks were 
similar to those involving dual therapy with metformin 
and sulphonylureas.
Comparison with previous studies
Clinical trial evidence for newer hypoglycaemic agen-
cies, such as glitazones and gliptins, has been largely 
based on surrogate endpoints such as reduction of 
HbA1c rather than hard clinical endpoints such as 
reduced incidence of complications as in our study. The 
UKPDS-34 study3  provided the original clinical trial evi-
dence for the use of metformin as first line treatment of 
choice for patients with type 2 diabetes since it was 
associated with a greater reduction in diabetes related 
endpoints and fewer hypoglycaemic attacks than sul-
phonylureas. Designed in the 1970s and running over a 
20 year period, part of the UKPDS cohort was ran-
domised with 342 patients randomised to metformin 
and 411 patients to diet alone. The researchers reported 
a 32% reduction (95% confidence interval 13% to 47%) 
for any diabetes related endpoint.3 Although the num-
bers randomised to each arm were small and the num-
bers of clinical endpoints even smaller (there were only 
six events of amputation in the metformin group and 
nine in the diet alone group), the results are compara-
ble with the reduction in risk reported in our study for 
metformin monotherapy compared with diet only.
strengths and limitations
Ideally we would now have ongoing published 
meta-analyses of randomised trials comparing clinical 
outcomes among patients prescribed different diabetes 
drugs alone and in combination compared with no 
medication. These meta-analyses would form the basis 
of national guidelines and robust systems would be in 
place to routinely monitor the use of these drugs for 
unintended or adverse outcomes. However, nearly all 
clinical trials of diabetes drugs have been designed 
using intermediate or surrogate outcomes such as 
changes in HbA1c rather than relevant clinical out-
comes. The criteria set by regulators regarding new dia-
betes agents12 13 and the impracticability of undertaking 
adequately powered head to head trials of clinical out-
comes for existing drugs means that we need to use 
alternative methods for establishing the necessary evi-
dence base for clinical outcomes. Therefore, the ques-
tion becomes how best to assemble the evidence for 
table 5 | adjusted hazard ratios (95% Ci) for each study outcome* compared with metformin monotherapy
study outcome
blindness Hyperglycaemia Hypoglycaemia amputation Kidney failure
Monotherapy
 Metformin alone 1.00 1.00 1.00 1.00 1.00
 Sulphonylureas alone 1.42 (1.25 to 1.62) 1.38 (1.25 to 1.52) 7.32 (6.55 to 8.18) 1.44 (1.20 to 1.71) 2.63 (2.25 to 3.06)
 Insulin alone 1.96 (1.50 to 2.55) 2.48 (2.11 to 2.92) 21.17 (18.48 to 24.25) 2.68 (2.08 to 3.46) 2.88 (2.32 to 3.57)
 Glitazones alone 0.98 (0.31 to 3.03) 1.50 (0.78 to 2.89) 1.83 (0.59 to 5.70) 1.88 (0.60 to 5.84) 2.55 (1.13 to 5.74)
 Gliptins alone 1.39 (0.66 to 2.93) 1.44 (0.85 to 2.43) 0.83 (0.21 to 3.33) 1.03 (0.33 to 3.20) 3.52 (2.04 to 6.07)
 Other hypoglycaemic agents alone 0.82 (0.26 to 2.55) 0.32 (0.08 to 1.29) 6.44 (3.63 to 11.42) — 1.17 (0.63 to 2.18)
Dual therapy
 Metformin and sulphonylureas 0.94 (0.85 to 1.04) 1.02 (0.95 to 1.09) 6.03 (5.47 to 6.63) 1.08 (0.95 to 1.23) 0.76 (0.62 to 0.92)
 Metformin and insulin 1.58 (1.21 to 2.07) 1.95 (1.63 to 2.34) 14.34 (12.40 to 16.59) 1.78 (1.34 to 2.37) 1.13 (0.65 to 1.98)
 Metformin and glitazones 0.87 (0.58 to 1.29) 0.60 (0.45 to 0.80) 1.35 (0.89 to 2.05) 0.57 (0.30 to 1.06) 0.71 (0.33 to 1.50)
 Metformin and gliptins 0.72 (0.49 to 1.04) 0.78 (0.62 to 0.97) 1.23 (0.84 to 1.80) 0.84 (0.55 to 1.30) 0.59 (0.28 to 1.25)
 Metformin and other hypoglycaemic agents 0.83 (0.50 to 1.38) 1.06 (0.79 to 1.41) 2.77 (1.92 to 4.01) 0.93 (0.51 to 1.70) 0.57 (0.18 to 1.79)
 Sulphonylureas and insulin 2.13 (1.47 to 3.09) 2.62 (1.89 to 3.63) 23.91 (19.89 to 28.75) 2.15 (1.40 to 3.29) 3.56 (2.64 to 4.82)
 Sulphonylureas and glitazones 0.80 (0.38 to 1.69) 1.93 (1.21 to 3.07) 13.22 (10.04 to 17.39) 2.06 (1.13 to 3.76) 2.14 (1.27 to 3.61)
 Sulphonylureas and gliptins 1.32 (0.78 to 2.25) 0.98 (0.57 to 1.69) 5.93 (4.12 to 8.53) 1.30 (0.69 to 2.45) 3.21 (2.08 to 4.93)
 Sulphonylureas and other hypoglycaemic agents 0.69 (0.17 to 2.76) 0.73 (0.24 to 2.27) 12.12 (7.57 to 19.41) 2.02 (0.75 to 5.43) 2.38 (1.11 to 5.09)
Triple therapy
 Metformin, sulphonylureas, and insulin 1.36 (0.97 to 1.89) 1.46 (1.12 to 1.91) 13.17 (11.14 to 15.57) 1.30 (0.88 to 1.91) 1.06 (0.53 to 2.16)
 Metformin, sulphonylureas, and glitazones 0.67 (0.48 to 0.94) 0.99 (0.79 to 1.25) 6.32 (5.35 to 7.45) 0.70 (0.47 to 1.05) 1.21 (0.75 to 1.96)
 Metformin, sulphonylureas and gliptins 0.82 (0.62 to 1.08) 1.09 (0.91 to 1.32) 5.07 (4.28 to 6.00) 0.99 (0.73 to 1.33) 0.68 (0.39 to 1.20)
 Metformin, sulphonylureas and other hypoglycaemic 
agents
0.91 (0.59 to 1.43) 1.03 (0.76 to 1.38) 4.31 (3.26 to 5.68) 0.85 (0.50 to 1.45) 0.93 (0.38 to 2.26)
 All other drug combinations 0.94 (0.64 to 1.39) 1.43 (1.14 to 1.80) 9.02 (7.50 to 10.83) 1.25 (0.86 to 1.82) 1.60 (0.98 to 2.62)
No medication 1.40 (1.29 to 1.52) 1.58 (1.51 to 1.65) 3.06 (2.77 to 3.37) 1.44 (1.28 to 1.62) 1.85 (1.61 to 2.12)
Treatment categories are mutually exclusive.
*Hazard ratios adjusted for sex; age; duration since diagnosis of diabetes (five levels); ethnicity (nine levels); Townsend deprivation score; smoking status (five levels); use of anticoagulants, 
thiazides, ACE inhibitors, angiotensin 2 blockers, calcium channel blockers, statins, aspirin; existing complications (blindness, hyperglycaemic coma, hypoglycaemia, amputation, severe 
kidney failure); hypertension; cardiovascular disease; atrial fibrillation; chronic renal disease; rheumatoid arthritis; valvular heart disease; peripheral vascular disease; body mass index; 
systolic blood pressure; HbA1c; serum creatinine; and cholesterol:high density lipoprotein ratio.
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clinical outcomes using observational linked data 
sources, how to minimise attendant biases, and how to 
interpret the findings with due caution.
Generalisability
To our knowledge, this is the largest study based on an 
ethnically diverse contemporaneous, representative 
population of patients with type 2 diabetes. We included 
all eligible patients to minimise selection bias. 
 Therefore, we think the results are likely to be general-
isable to similar populations of patients with type 2 dia-
betes.
Clinical outcomes
Strengths of our analysis were the inclusion of hard 
clinical endpoints based on clinical diagnoses or proce-
dural codes recorded on at least one of three linked 
electronic data sources. Use of all three linked data 
sources was designed to minimise under-ascertainment 
of outcomes, which would otherwise lead to under-esti-
mation of absolute risks. The clinical outcomes were 
based on clinical diagnoses made by the treating clini-
cian or hospital procedural codes rather than formally 
adjudicated events as would occur in a clinical trial. 
Although some patients may have been incorrectly 
recorded as having a particular outcome, UK general 
practices have good levels of accuracy and complete-
ness in recording clinical diagnoses.44  Also, the diag-
nostic validity of such diagnoses in general practice has 
been shown to be high.45 Possible ascertainment bias of 
outcomes is unlikely to vary according to the type of 
hypoglycaemic prescribed so would not explain the 
associations we have found.
Exposure to medication
We had detailed exposure information on hypoglycae-
mic agents prescribed throughout the follow-up period, 
enabling us to develop a detailed categorisation of drug 
exposure time with 20 different treatment groups 
including combinations of treatments. This categorisa-
tion enabled us to account for switching between differ-
ent treatments or treatment combinations, and we were 
able to account for real world prescribing patterns over 
a long period, allowing multiple comparisons not only 
between drugs but also between different drug combi-
nations. The recording of prescriptions issued in UK 
general practices has very high levels of complete-
ness.46  Our study analysed prescribed medication 
rather than medication actually taken by the patients, 
although renewal of prescriptions is likely to indicate 
drug use because patients need to initiate repeat pre-
scriptions. This could result in misclassification of 
exposure if patients were prescribed medication that 
they did not actually take and could underestimate 
associations between diabetes drug use and clinical 
outcomes. Unlike previous studies, we have included 
comparisons of risk against periods of no treatment6 as 
well as against metformin monotherapy. The first com-
parison is important because about 40% of patients 
with type 2 diabetes are managed without hypoglycae-
mic treatments throughout follow-up.
Our study included over 55 000 person years of expo-
sure to glitazones. The predominant glitazone was 
pioglitazone, which was prescribed to 90% of the glita-
zone users. Our study included over 70 000 person 
years of exposure to gliptins, which represents one of 
the largest studies to date. The predominant gliptin pre-
scribed in our dataset was sitagliptin, which was pre-
scribed to 80% of those gliptin users. There are 
currently too few patients prescribed linagliptin, 
saxagliptin, and vildagliptin to support separate 
 analyses by individual drug; this was a limitation of the 
study because there may be differences between indi-
vidual gliptins and their effect on HbA1c.47 However, the 
numbers of patients on different types of gliptin is likely 
to increase over time and further analyses can be under-
taken once more data has accrued. We did not split the 
other drug classes such as sulphonylureas into different 
drug subtypes because they were not the main focus of 
the study, but potential heterogeneity could exist in risk 
of the outcomes across different subtypes for each drug 
class in the analyses.
Assessment of other types of bias
Other types of bias that can affect observational studies 
include recall bias, indication bias, and channelling 
bias. Recall bias will not have occurred because data on 
prescriptions for hypoglycaemia and confounding vari-
ables were recorded before the clinical outcomes. We 
restricted the study population to patients with type 2 
diabetes to limit indication bias (which occurs when 
patients are prescribed drugs for a condition associated 
with the risk of the adverse event under consideration). 
We used an incident user design to reduce confounding 
and biases that can otherwise arise from adjustment for 
intermediate characteristics in the causal path.27  We saw 
some differences at baseline between patients prescribed 
different treatment groups (tables 1 and 2), although 
these were predominantly increased levels of comorbid-
ities for insulin and lower levels of concurrent use of 
medication (such as statins and aspirin) for metformin.
To reduce channelling bias (where the choice of a 
particular drug is influenced by patient characteristics), 
we adjusted for a wide range of potential confounding 
variables including demographic characteristics, differ-
ent comorbidities, clinical values, and concurrent med-
ication. We decided to use the most recent clinical 
values before changes in treatment since these are the 
values most likely to be used to inform those decisions. 
We did not use repeated values or changes in values 
over long periods because these data are not necessar-
ily recorded consistently and would tend to increase 
proportions of missing data. However, we are unable to 
exclude the possibility of residual confounding since 
there may be other unmeasured patient characteristics 
that affected selection of hypoglycaemic agents.
As in other similar studies,28  we excluded prevalent 
users of insulin at baseline but left patients subse-
quently prescribed insulin in for the rest of the analysis 
because it is part of the treatment ladder and some of 
these patients will also have had other medications of 
interest during follow-up. Although insulin was not the 
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primary exposure of interest, patients prescribed insu-
lin had higher risks of all complications (tables 3 and 5 ) 
despite adjustment for higher levels of comorbidity. It is 
unlikely that this increased risk was a direct result of 
treatment with insulin. Instead, residual confounding 
and reverse causality could have occurred—that is, the 
insulin treated group was at much higher risk of com-
plications than the groups treated with diet or oral med-
ication, and it is this that results in their apparently 
worse outcomes and not their treatment with insulin. 
For example, in table 2, the insulin treated group had 
the highest HbA1c and creatinine values before treat-
ment, although both factors were adjusted for in the 
analyses. An alternative explanation could be that 
patients have symptoms that lead to an amputation or 
sight problems before being diagnosed with these con-
ditions and that the symptoms are associated with sub-
sequent use of insulin rather than glitazones or gliptins.
Although randomised controlled trials of hypogly-
caemic treatments are not influenced by residual con-
founding, they tend to be small, of short duration, and 
might not report on relevant clinical outcomes. An 
alternative design would an observational study of a 
cohort of patients specifically assembled for the pur-
pose rather than routinely collected data as in our 
study. Studies using routinely collected data are sus-
ceptible to missing data, but in our study, over 99% of 
patients had smoking status recorded, 87% had ethnic 
group recorded, and over 82% had of patients had com-
plete data for all five clinical values (table 2). We also 
used multiple imputation to impute missing data. Other 
problems with routine data include coding errors and 
variable timing between measurements of risk factors 
in patients because of differences in when patients 
present to their general practitioner. Advantages of 
using routinely collected data rather than a purposeful 
cohort include size, efficiency, better generalisability, 
and less susceptibility to selection bias or attrition bias.
We fitted several different models and carried out 
sensitivity analyses that showed some heterogeneity of 
results. The results are therefore sensitive to the 
assumptions made in the study design and modelling 
and have uncertainty; however, our findings were gen-
erally consistent across the different analyses for glita-
zones and gliptins.
Conclusions
We have found lower risks of hyperglycaemia among 
patients prescribed dual therapy involving metformin 
with either gliptins or glitazones compared with met-
formin alone. Compared with metformin monother-
apy, triple therapy with metformin, sulphonylureas, 
and either gliptins or glitazones was associated with 
an increased risk of hypoglycaemia, which was similar 
in magnitude to the risk for dual therapy with met-
formin and sulphonylureas. Compared with met-
formin monotherapy, triple therapy with metformin, 
sulphonylureas, and glitazones was associated with a 
reduced risk of blindness. These results, while subject 
to residual confounding, could have implications for 
prescribing of hypoglycaemic drugs.
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